Document Detail

Local application of tacrolimus in distal colitis: feasible and safe.
MedLine Citation:
PMID:  18825773     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Tacrolimus is a potent immunomodulator that is effective in the systemic treatment of inflammatory bowel diseases (IBD). However, potential toxicity and systemic (side) effects after oral intake limit its use. We investigated the local applicability and safety of tacrolimus for distal colitis. METHODS: Patients with refractory left-sided colitis or proctitis were treated for 4 weeks with a daily tacrolimus 2-4 mg enema or 2 mg suppository. Safety of local tacrolimus treatment was assessed by measurement of whole blood tacrolimus trough levels by monitoring liver and kidney function and blood glucose levels. Efficacy of treatment was assessed by comparing the disease activity index (DAI) in ulcerative colitis (UC) patients and endoscopic and histologic appearances before and after 4 weeks of treatment. RESULTS: Nineteen patients with left-sided colitis (n = 7) or proctitis (n = 12) were treated. Two patients with left-sided colitis had Crohn's disease (CD), the other 17 patients had UC. None of the patients developed side effects. Blood trough levels of tacrolimus were too low to induce systemic immune suppression. Thirteen of 19 patients (3/5 left-sided UC, 0/2 left-sided CD, and 10/12 proctitis) showed clinical improvement of disease activity after 4 weeks of local tacrolimus treatment. Moreover, a significant improvement of histological appearance was observed in the suppository-treated group. CONCLUSIONS: This study demonstrates that local colonic application of tacrolimus 2-4 mg daily in patients with refractory distal colitis is feasible, probably safe, and potentially efficacious, and therefore opens the need for a further, randomized trial.
Jolanda M van Dieren; Ad A van Bodegraven; Ernst J Kuipers; Eke N Bakker; Alexander C Poen; Herman van Dekken; Edward E S Nieuwenhuis; C Janneke van der Woude
Related Documents :
8168553 - Infectious complications in 100 consecutive heart transplant recipients.
23415963 - Diurnal temperature change is associated with testicular torsion-a nationwide populatio...
23102873 - Use of botulinum toxin type a to improve treatment of facial wounds: a prospective rand...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Inflammatory bowel diseases     Volume:  15     ISSN:  1536-4844     ISO Abbreviation:  Inflamm. Bowel Dis.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-01-14     Completed Date:  2009-07-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9508162     Medline TA:  Inflamm Bowel Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  193-8     Citation Subset:  IM    
Department of Gastroenterology & Hepatology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Colitis / drug therapy*,  pathology*
Immunosuppressive Agents / administration & dosage*
Suppositories / administration & dosage
Tacrolimus / administration & dosage*
Treatment Outcome
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Suppositories; 109581-93-3/Tacrolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhanced CBir1-specific innate and adaptive immune responses in Crohn's disease.
Next Document:  The rheological properties of modified microcrystalline cellulose containing high levels of model dr...